It is recognized that donor factors contribute to lung transplant outcomes. Recent observations and studies have started to elucidate potential mechanisms behind explaining these observations. This perspective piece summarizes evolving lung transplant literature on the subject, focusing on donor "passenger" organisms, cells, hormones, and proteins transferred to the recipient. Many extrinsic and intrinsic donor features or properties have important consequences for subsequent allograft function in the recipient. Potentially, a better understanding of these features may provide useful novel therapeutic targets to enhance allograft outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.healun.2019.06.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatic Sinusoidal Obstruction Syndrome (SOS) Associated with Checkpoint Inhibitor Therapy.
Eur J Case Rep Intern Med
December 2024
Department of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Unlabelled: Sinusoidal obstruction syndrome (SOS) is a distinctive and potentially fatal form of hepatic injury that mainly occurs after hematopoietic-stem cell transplantation but also due to many other conditions including drug or toxin exposure. Recently, immune checkpoint inhibitors (ICIs) have revolutionised the treatment of many solid organ malignancies. Furthermore, as their use has become more widespread, rare toxicities have emerged.
View Article and Find Full Text PDFA National Resource Sharing Program Is Feasible Even in Challenging Lung Recoveries.
Ann Thorac Surg Short Rep
December 2023
Division of Cardiothoracic Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska.
Background: Mobile ex vivo lung perfusion (mEVLP) allows transportation of lung allografts while maintaining ventilation and perfusion and has demonstrated safety and efficacy with the potential to expand organ utilization. A nationwide organ recovery service has been implemented to provide surgical expertise for recovery alongside mEVLP transportation services.
Methods: We reviewed patients at our institution who underwent lung transplantation with donor lungs procured with this program.
Noninflammatory Causes of Pulmonary Edema During Ex Vivo Lung Perfusion.
Ann Thorac Surg Short Rep
December 2024
Toronto Lung Transplant Program, Toronto General Hospital, Toronto, Canada.
Ex vivo lung perfusion (EVLP) is used to evaluate donor lungs prior to lung transplantation. Development of pulmonary edema during EVLP is generally thought to represent inflammatory breakdown of the air-fluid barrier and these lungs are declined for transplant. We present the case of a donor lung that underwent stapled wedge resection during cold storage for air leak and the subsequent development of profound (∼650 mL) pulmonary edema around the staple line during EVLP.
View Article and Find Full Text PDFDonor Specific Antibodies in Extracorporeal Membrane Oxygenation-Bridged Lung Transplant Recipients.
Ann Thorac Surg Short Rep
December 2024
Department of Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Background: Extracorporeal membrane oxygenation (ECMO) is increasingly used as a bridge to lung transplantation. Although other mechanical circulatory support devices have been associated with anti-human leukocyte antigen antibody formation, including de novo donor-specific antibodies (dnDSA), it is unknown whether ECMO is a sensitizing exposure.
Methods: This was a single-center retrospective cohort study of lung transplant recipients.
Sarcopenia Predicts Outcomes After Lung Transplantation in Older Lung Transplant Candidates.
Ann Thorac Surg Short Rep
March 2023
Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California.
Background: As lung transplantation (LT) expands to older recipients, objective approaches to evaluate the aging are needed to optimize posttransplantation outcomes. Frailty assessment and sarcopenia have shown promise as tools for predicting clinical outcomes.
Methods: Patients older than 55 years undergoing evaluation for LT were enrolled in an institutional review board-approved study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!